EVELYNE M LOYER to Infusions, Intravenous
This is a "connection" page, showing publications EVELYNE M LOYER has written about Infusions, Intravenous.
Connection Strength
0.047
-
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer Chemother Pharmacol. 2004 Jan; 53(1):1-7.
Score: 0.012
-
Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer. 2001 Nov 01; 92(9):2327-33.
Score: 0.010
-
Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan. Ann N Y Acad Sci. 2000; 922:349-51.
Score: 0.009
-
A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res. 1997 Sep; 3(9):1501-5.
Score: 0.008
-
An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs. 1997 Aug; 8(7):657-61.
Score: 0.008